- Home
- VRAX vs SILO Comparison
VRAX vs SILO Comparison
Compare VRAX & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VRAX | SILO |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Apparel |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 4.6M |
| IPO Year | 2021 | 2011 |
Fundamental Metrics
Financial Performance| Metric | VRAX | SILO |
|---|---|---|
| Price | $0.16 | $0.34 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $1.00 | N/A |
| AVG Volume (30 Days) | 148.8K | ★ 212.1K |
| Earning Date | 03-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.83 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $72,102.00 |
| Revenue This Year | $217,274.83 | $1.86 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.17 | $0.22 |
| 52 Week High | $1.34 | $1.23 |
Technical Indicators
Market Signals| Indicator | VRAX | SILO |
|---|---|---|
| Relative Strength Index (RSI) | 33.39 | 49.70 |
| Support Level | N/A | $0.33 |
| Resistance Level | $0.25 | $0.38 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 12.37 | 50.50 |
Price Performance
Historical ComparisonAbout VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.